Envestnet Asset Management
LRMR icon

Envestnet Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Envestnet Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,525
Closed -$137K – 4422
2024
Q4 		$137K Buy
35,525
+3,877
+12% +$25.6K ﹤0.01% 4169
2024
Q3 		$207K Buy
31,648
+5,731
+22% +$46.1K ﹤0.01% 4006
2024
Q2 		$188K Sell
25,917
-1,200
-4% -$9.19K ﹤0.01% 3947
2024
Q1 		$206K Buy
+27,117
New +$211K ﹤0.01% 3932

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Envestnet Asset Management's LRMR Position: Q1 2025 in Review

Envestnet Asset Management sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 35,525 shares — an estimated $137K sold.

Envestnet Asset Management first reported a position in LRMR in Q1 2024 and held it in 4 quarters. The position peaked at $207K in Q3 2024. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

  • Envestnet Asset Management reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 35,525 Larimar Therapeutics shares in Q1 2025, an estimated $137K.
  • Envestnet Asset Management first reported a position in Larimar Therapeutics in Q1 2024 and held it in 4 quarters.
  • Envestnet Asset Management's Larimar Therapeutics position peaked at $207K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on Envestnet Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.